Daiichi Sankyo has announced that, as a result of ongoing efforts to review its global R&D structure to increase R&D productivity, the company has decided to further reorganize its R&D structure by closing its Japanese research subsidiary, Asubio Pharma by the end of March 2018.
Asubio Pharma has approximately 150 employees and mainly focuses on psychiatric and neurological diseases, immune and inflammatory diseases and regenerative medicine, conducting research based on its position a drug discovery venture within Daiichi Sankyo Group.
Under this reorganization, Daiichi Sankyo plans to transfer Asubio Pharma R&D functions and employees to other Daiichi Sankyo Group companies in Japan. We expect the integration of the venture spirit of Asubio Pharma into other Daiichi Sankyo research activities to contribute greatly to improving R&D productivity.
Further details regarding the reorganization scheme will be announced in the future.